Banks and miners are typically the first ASX that come to mind when hunting for decent yields. However, after a tremendous rally in the Big Four banks, an investment in the likes of ( ) just isn't quite the no-brainer buy it once was. But what if I knew of a company dishing up more than twice the a delicious amount of potential capital ? Sounds like the holy grail of investments, right? Or at least one heck of an opportunity for someone hoping to strike a balance between income and growth. Don't worry; it's not a figment of my imagination. The company is ( ), and despite posting a sensational in August, shares in this billion-dollar business are down almost 8% this year. Is this ASX dividend stock really paying a 6% yield? The short answer is . The salary packaging, fleet management, and novated lease provider has paid 49.5 cents per share in dividends in the last year. This works out to be a of 6.2% based on the current share price. There's a longer answer, too. Part of the 49.5 cents is a dividend. If we remove the 16 cents attributed to a special payment — which usually means it's a one-off — the yield reduces to 4.2%. Nothing to sneeze at, but a savings account might hand out more. What's important to know, though, is that Smartgroup has paid this special dividend for four years in a row. It doesn't mean it will be paid again next year, but four years running sets quite the precedent for possibly even cranking up the baseline payment. It all comes down to profits. If Smartgroup's profits flatline or fall, then there's a slim chance of an increase in dividends. Conversely, if the business can continue to grow, then the income component can also expand. I'm buying more, and not because of the dividends This is where it gets exceptionally interesting for Smartgroup. While the ASX stock has dividend credentials, the growth on display is beyond what you might normally expect from a high-yielding investment. In the latest half-year result, Smartgroup's revenue increased 27% to $148.5 million, and bottom-line profits increased 16% to $34.1 million. Consensus estimates have the company earning in the region of in FY25. Today, Smartgroup has a of $1,070 million. If we calculate the forward , it comes out at around 14 times FY25 earnings. That's a fairly low multiple for a company posting decent growth. If I had to guess, my fair value for this ASX dividend stock would be approximately $10.50 per share. Meanwhile, shares were trading hands at $8.01 at the close yesterday, which means there could be 31% of capital appreciation around the corner. In saying that, I'm a long-term holder of Smartgroup. While the short term looks extremely compelling, the potential in the long run is even sweeter.Celebrities who had the worst year in 2024Diffuse Large B-cell Lymphoma | Image Credit: © Свет Лана – stock.adobe.com Data from a retrospective medical chart review shared during the 2024 ASH Annual Meeting confirmed the real-world effectiveness of tafasitamab-cxix (Monjuvi) use in US patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and shed light on certain factors associated with survival. 1 At a median follow-up time of 14.7 months (range, 8.5-17.1) from tafasitamab initiation, the real-world progression-free survival (PFS) with tafasitamab was 11.3 months (95% CI, 9.8-13.6) in the overall population (n = 181), and the real-world overall survival (OS) was 24.8 months (95% CI, 17.8-not evaluable [NE]). The real-world overall response rate (ORR) to the agent was 73.5%, which comprised a complete response (CR) rate of 23.2% and a partial response (PR) rate of 50.3%. In the patients who achieved a real-world CR or PR with the agent (n = 133), the real-world duration of response (DOR) was 9.6 months (95% CI, 8.3-13.3). A multivariable analysis showed that factors significantly linked with increased risk of progression included receiving the agent in the third to fifth line (n = 51) vs the second line (n = 130; HR, 1.79; 95% CI, 1.20-2.66; P = .004), having Ann Arbor stage III to IV disease (n = 169) vs stage I to II (n = 10; HR, 0.30; 95% CI, 0.10-0.95; P = .041), increasing Charlson Comorbidity Index scores (n = 181; HR, 1.43; 95% CI, 1.03-1.97; P = .033), and bulky (n = 36) vs non-bulky (n = 145) disease (HR, 1.96; 95% CI, 1.26-3.05; P = .003). To overcome violation of proportional hazards assumption caused by the variable of ECOG performance status, coefficients had been adjusted for status of 2 or higher vs under 2 through stratifying the model on performance status. Moreover, a cox proportional hazards model showed that factors significantly associated with increased risk of mortality included receiving tafasitamab in the third to fifth line vs the second line (HR, 2.39; 95% CI, 1.46-3.93; P < .001), increasing age (HR, 1.06; 95% CI, 1.03-1.09; P < .001), ECOG performance status of 2 or higher (n = 86) vs below 2 (n = 95; HR, 3.57; 95% CI, 2.13-5.97; P < .001), and bulky vs non-bulky disease (HR, 2.22; 95% CI, 1.27-3.87; P = .005). “The additional follow-up from the initial data collection allowed for a more robust evaluation of the real-world effectiveness of tafasitamab in patients with relapsed or refractory DLBCL, predominantly in the community practice setting,” lead study author Kim Saverno, PhD, of Incyte Corporation, in Wilmington, Delaware, said in a poster presentation of the data. “These results support a real-world clinical benefit for tafasitamab, with the greatest benefit observed when [the agent] was received in second vs later lines of therapy.” The CD19-targeted immunotherapy, tafasitamab, was approved by the FDA in July 2020 for use in combination with lenalidomide (Revlimid) in adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not candidates to undergo autologous stem cell transplant. 2 To date, few studies have evaluated the agent in a US real-world setting, according to Saverno. 1 She added that data from a real-world study were previously shared, but had a limited follow-up time of 6.5 months, which “precluded robust evaluations of the clinical effectiveness” of the agent. 3 For the current retrospective, multisite, medical chart review, 23 physicians from Cardinal Health’s Oncology Provider Extended Network abstracted data from 181 eligible patients’ medical records into electronic case report forms. Notably, 83% of these physicians practiced in the community. 1 For patients to be considered eligible for the analysis, they must have started treatment with tafasitamab with or without concomitant lenalidomide for relapsed/refractory disease on or following October 21, 2020; be at least 18 years old at the time treatment with the agent was started; and have undergone at least 4 months of follow-up since treatment started. Those who died during this 4-month interval were still permitted. If patients received the agent as part of an interventional clinical trial, they were excluded. A total of 182 patients met the prespecified eligibility criteria; 1 patient who received tafasitamab only as bridge therapy to CAR T-cell therapy was excluded. As such, a total of 181 patients were included in the study; 144 of these patients were still alive at last follow-up of initial data collection which had occurred between February 22, 2023, and March 29, 2023. Of those patients, 137 patients had additional follow-up data available and underwent additional data collection between December 18, 2023, and January 31, 2024. A total of 106 patients were alive at last follow-up. “Data collected at the two time points were merged and descriptive statistics were used to summarize the results,” Saverno explained. “Kaplan-Meier analyses were used to calculate time-to-event end points and multivariable Cox analyses were used to assess factors associated with real-world PFS and OS.” In the 181 total patients, the median age at the time of tafasitamab initiation was 71.1 years (range, 65.0-75.5). Most patients were White (64.1%), and more than half of patients were male (56.4%). Regarding Ann Arbor stage at time of treatment initiation, 5.5% had stage I or II disease, 93.4% had stage III or IV disease; this information was unknown for 1.1% of patients. ECOG performance status at the time of treatment initiation was 0 to 1 for 52.5% of patients and 2 or higher for 47.5% of patients. Revised International Prognostic Index for Diffuse Large B-cell Lymphoma was 3 to 5 for 80.5% of patients and 1 to 2 for 19.5% of patients. “Over 70% of patients received tafasitamab in the second line, and 71% of patients had discontinued tafasitamab at the last follow-up, mostly due to disease progression,” Saverno noted. “Over half of the patients were still alive at the last follow-up, and among the patients still alive, half [were] still receiving tafasitamab at the time of the most recent follow-up.” Additional treatment outcome data showed that in those who received tafasitamab in the second line (n = 130), the real-world ORR was 78.5%; this was comprised of a CR rate of 27.7% and a PR rate of 50.8%. For this group, the stable disease (SD) rate was 8.5%, the progressive disease (PD) rate was also 8.5%, and 4.6% of patients did not have these data available. In the group of patients who received the immunotherapy in the third line (n = 43), the real-world ORR was 62.8%; this comprised a CR rate of 11.6% and a PR rate of 51.2%. In this subset, the SD and PD rates were 18.6% and 11.6%, respectively; 7.0% of patients did not have these data available. In patients who experienced a real-world CR as a best response to tafasitamab (n = 42), the median real-world DOR was 19.2 months (95% CI, 8.8-NE). In those who achieved a real-world PR as a best response to the agent (n = 91), the median real-world DOR was 8.5 months (95% CI, 6.8-10.0). “This study is impacted by limitations inherent to real-world studies, such as unobserved and missing data,” Saverno concluded. “The number of participating oncologists was small and thus may not reflect the treatment patterns of all US oncologists managing patients with DLBCL.” Disclosures: Dr Saverno cited employment and stock ownership with Incyte Corporation.
Chandigarh: A coordination committee of Punjab, Haryana and western Uttar Pradesh was formed on Saturday to fight “divisive forces” in India at Sada Bhaichara (unity conference) programme organised by Misl Satluj, a socio-political body, at Kisan Bhawan, Chandigarh. Speakers at the gathering stressed on coming together and “join forces against the divisive politics of the BJP and RSS”. Supreme Court lawyer Mahmood Parcha stressed on “the importance of returning to ballot baper and saving the Constitution”. Giving the slogan of “EVM hatao, ballot paper lao (Replace EVMs with ballot papers),” he added. tnn We also published the following articles recently Markadwadi votes on ballot paper today to challenge EVM data Markadwadi villagers in Solapur, Maharashtra, are holding a symbolic re-poll using ballot papers to challenge the Election Commission of India's results. They allege discrepancies in the EVM count, claiming the BJP candidate's lead contradicts local support for the winning NCP (SP) candidate. Markadwadi in Solapur to vote on ballot paper today to challenge EVM Markadwadi villagers in Solapur, primarily MVA supporters, are holding a symbolic re-poll using ballot papers on Tuesday, contesting the Election Commission's results showing a BJP lead in their village. They allege discrepancies in the EVM count, despite the official declaration of NCP's Uttamrao Jankar as the winner in the Malshiras constituency. In unofficial 'repoll', Maharashtra's Solapur to vote today on ballot paper to challenge EVMs Markadwadi villagers, primarily MVA supporters, are conducting a symbolic re-poll using ballot papers, disputing the official EVM results that showed a BJP lead. Despite administrative warnings and police presence, they aim to demonstrate their support for the winning NCP candidate. BJP supporters are boycotting the unofficial poll, dismissing it as unnecessary. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .Rihanna and boyfriend A$AP Rocky make a stylish appearance as they arrive arm-in-arm to Design Miami Have YOU got a story? Email tips@dailymail.com By ALESIA STANFORD FOR DAILYMAIL.COM Published: 07:41 AEDT, 9 December 2024 | Updated: 07:48 AEDT, 9 December 2024 e-mail View comments Rihanna and her partner A$AP Rocky turned heads as they arrived to the Design Miami expo in South Florida on Sunday. The couple, who enjoyed a romantic dinner date on Saturday , put their chic style on full display at the annual design fair that showcases a curated selection of collectible design galleries and special projects from the 20th and 21st centuries. For the occasion, Rihanna, 36, flaunted her enviable curves in a strapless black minidress and a feathered stole around her shoulders. The Grammy winner completed her look with a pair of ripped, black stockings. The Diamonds artist wore her long dark hair straight and her makeup looked natural beneath the harsh convention floor lights. She accessorized with three necklaces; a thick gold choker, and two featuring thin gold chains and pendants. Rihanna and her partner A$AP Rocky turned heads as they arrived to the Design Miami expo in South Florida on Sunday View this post on Instagram A post shared by The Cut (@thecut) Rocky, 36, looked dapper in double denim. His look included a button down shirt partially tucked into his straight leg jeans with a rolled up hem. Read More Rihanna shows off her effortlessly cool style in a mesh jersey and frayed jeans The Tailor Swif artist wore black shoes and a large gold belt buckle with gold lettering. The couple attended the event, which is part of the annual Art Basal, to promote the latest addition to the rapper-turned-designer's HOMMEMADE line. Video, shared by The Cut, shows Rihanna checking out her Rocky's futuristic looking installation. She picked up a keyboard and touched the keys while photographers snapped photos. Information on the backdrop indicated it was part of the Galaxy collection. 'The Royal Couple has hit Miami,' the outlet wrote next to the clip. '@badgalriri and @asaprocky arrive at @designmiami fair at #artbasal to celebrate A$AP’s installation for his brand @hommemade’s Galaxy Collection.' The couple, who enjoyed a romantic dinner date on Saturday , put their chic style on full display at the annual design fair that showcases a curated selection of collectible design galleries and special projects from the 20th and 21st centuries For the occasion, Rihanna, 36, flaunted her enviable curves in a strapless black minidress and a feathered stole around her shoulders The clip shows the Umbrella singer giving a big hug to a young friend. Both Rocky and Rihanna have been focusing their artistic talents on design. He collaborated on a capsule clothing collection with Parisian designer Marine Serre in 2021 and has now turned his focus on furniture. 'I’m into design, I’m into detail, I’m into elevated taste value,' he told GQ that year. She has been creating a variety of undergarments via her Savage x Fenty line since 2019. ASAP Rocky Rihanna Share or comment on this article: Rihanna and boyfriend A$AP Rocky make a stylish appearance as they arrive arm-in-arm to Design Miami e-mail Add commentEquinix Inc. stock rises Thursday, still underperforms market
49ers QB Brock Purdy, DE Nick Bosa out, Brandon Allen to start at Green BayIndiana coach Mike Woodson is happy that his team has won three straight games but concerned that it's committing too many turnovers. Limiting miscues is at the top of his wish list for Monday night's Big Ten Conference opener against visiting Minnesota in Bloomington, Ind. While the Hoosiers (7-2) shot 53.8 percent and dominated Miami (Ohio) 46-29 on the glass during a 76-57 win at home Friday night, they also had more turnovers (16) than assists (15). Having played for Bob Knight at Indiana, Woodson is fanatical about his team executing its offense without making mistakes. "We were taking chances on passes that weren't there," Woodson said. "We have to fix it. If we start Big Ten play like that, it puts you in a hole." In between careless mistakes, the Hoosiers got a huge game out of Oumar Ballo, the Arizona transfer who had 14 points, 18 rebounds and six assists. It was his 35th career double-double but his first at Indiana. Ballo (12.7 points per game, 9.3 rebounds) is one of four players averaging double figures for the Hoosiers. They're led by Malik Reneau, who's hitting for 15.4 ppg on 58.9 percent shooting. While Indiana tries to fine-tune its game, the Golden Gophers (6-4, 0-1 Big Ten) aim to get to the .500 mark in conference play after absorbing a 90-72 beating Wednesday night against visiting Michigan State. There was good news for Minnesota in that game. Mike Mitchell Jr. returned to the lineup after missing seven games with a high ankle sprain and drilled 5 of 9 3-pointers in a 17-point performance. Mitchell's shooting should aid an attack that ranks 311th in Division I in 3-point percentage at 29.7 percent as of Sunday. "He's a difference-maker in terms of being able to space the floor," Gophers coach Ben Johnson said of Mitchell. "He provides offensive firepower and a guy who can make shots and take pressure off our offense." Dawson Garcia leads the team at 19 ppg, while Lu'Cye Patterson and Mitchell are scoring 10 ppg. The Hoosiers own a 109-69 lead in the all-time series. --Field Level MediaThe upcoming shutdown of the Capital Club in downtown San Jose creates a void for business and political meetings locally.A federal jury has awarded a Levittown woman $2 million after finding Nassau police officers falsely arrested her at her home in 2019, according to lawyers for the plaintiff and the defendants. The verdict, reached in Central Islip on Friday, comes nearly six years after Donna Cipley said officers forcibly removed her from her house on March 12, 2019, wearing nothing but a pajama bottom and a tank top despite the cold. In a news release at the time, police said officers went to her home because she was wanted for criminal contempt and that she hit one with a door and bent back a detective's thumb. She was charged with second-degree assault and resisting arrest. Those charges were later dropped, her attorney said. “This is a long-awaited vindication of this grandmother’s rights," said Cipley's attorney, Frederick K. Brewington. "Finally, after attacking her in her own home, parading her before cameras in handcuffs and charging her with crimes she did not commit, she has seen just a small bit of justice.” Oscar Michelen, the lead attorney for the county and the police officers, said the defendants had done nothing wrong and that the county would fight the verdict. The biggest news, politics and crime stories in Nassau County, in your inbox every Friday at noon. By clicking Sign up, you agree to our privacy policy . "We believe that the amount awarded for the false arrest was excessive, and that even the false arrest finding will eventually be overturned on appeal," he told Newsday. Nassau County spokesman Chris Boyle did not respond to a request for comment Saturday. Cipley, who was in her early 60s at the time of the arrest, claimed in her suit that Nassau officers had started harassing her family after her son, who had been hospitalized for a drug overdose in 2018, refused to become a police informant. She alleged that detectives visited her home, shining lights in the windows and ringing the doorbell. She also said in her suit that "at no point" was she ever "the subject of a criminal contempt charge." After her charges were dimissed in October 2019, Cipley filed her civil rights lawsuit in 2020 . She accused six officers of abuse, but Brewington and Michelen confirmed that the jury on Friday found only two officers, Det. Michael Mazzara and Det. Basil Gomez, liable. Cipley's original complaint accused the defendants of allegations including assault, battery, false arrest and malicious prosecution. The jury found the officers liable only for the false arrest, according to the attorneys. In October, a federal jury in Brooklyn awarded more than $2.3 million dollars to Robert Besedin Sr. , an Air Force veteran from Baldwin who alleged two Nassau County police officers threw him down concrete stairs during an encounter at his home in 2017. Newsday previously reported that there were 75 settlements or jury awards for lawsuits alleging police or prosecutorial misconduct between 2000 and January 2023 on Long Island, costing taxpayers at least $165 million.
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company’s cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder. The Company’s Board of Directors is reviewing a range of appropriate strategies to realize value from its assets. The Board has directed management to reduce operating costs while such alternatives are being explored. There can be no assurance that the exploration of strategic alternatives will result in any agreement or transaction, or as to the timing of any such agreement or transaction. Further, there can be no assurance that the Company will be able to reach an agreement, or consummate a transaction, with Mr. Lazar or receive the required consent of an existing securityholder to any such transaction. As previously disclosed, the Company does not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. In the event that the Company is not able to enter into a strategic transaction and/or secure additional funding, it may be forced to cease all business operations. In such event, the Company’s stockholders may lose a part or all of their investment in the Company. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com . Forward-looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements related to the Company’s exploration and review of strategic alternatives, its ability to identify and complete a transaction as a result of the strategic review process, including a potential transaction with David Lazar, its plans to reduce costs and conserve cash and Cyclacel’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These risks and uncertainties include the risk that the Company may not be successful in exploring strategic alternatives and consummating one or more strategic transactions on attractive terms, if at all; the Company’s actual reductions in spending as compared to anticipated cost reductions; the Company’s costs of continuing to operate as a public company; and the other risks described more fully in Cyclacel Pharmaceuticals’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2023 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2024. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov . Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Company: Paul McBarron, (908) 517-7330, IR@cyclacel.com © Copyright 2024 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL TM , today announced the closing of its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share for gross proceeds of $11 million, before deducting underwriting discounts and other related expenses. The Company’s shares began trading on the Nasdaq Capital Market on December 3, 2024 under the symbol “JUNS.” The Company intends to use the net proceeds from the Offering to fund the Phase II clinical trial of its product candidate JOTROL TM in patients with Parkinson’s Disease, Strategic Service Agreements to accelerate business activities in South-East Asia, research and development activities regarding evaluation of new product opportunities, payment of the outstanding annual license fees due to Aquanova AG, the repayment of debt, working capital and other general corporate purposes. Dominari Securities LLC acted as the lead underwriter, with Revere Securities LLC acting as the co-manager for the offering. Anthony, Linder & Cacomanolis, PLLC acted as legal counsel to Jupiter Neurosciences and ArentFox Schiff LLP acted as legal counsel to the Underwriters in connection with the offering. The Company’s Registration Statement on Form S-1 (File No. 333- 260183) relating to the securities being offered was previously filed with, and subsequently declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2024. The offering was made by means of a prospectus, forming part of the Registration Statement. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, copies of the prospectus relating to the offering may be obtained, when available, from Dominari Securities LLC by email at info@dominarisecurities.com , by standard mail to Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor New York, NY 10022, or by telephone at (212) 393-4500; or from Revere Securities LLC by email at contact@reveresecurities.com , by standard mail to Revere Securities LLC, 560 Lexington Avenue, 16th Floor, New York, NY 10022, or by telephone at +1 (212) 688-2350. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL TM , is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com . FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contacts Investor Relations Alison Silva, President & CBO a.silva@jupiterneurosciences.comNone
New York, NY, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (Nasdaq: GLLI, GLLIW, GLLIR, GLLIU) (“ Globalink ” or the “ Company ”), a special purpose acquisition company, announced today that its stockholders approved amendments to its charter and trust agreement to extend the deadline to complete its initial business combination and change the structure and cost of such extensions. Under the amended charter, Globalink may extend the deadline to complete its initial business combination by up to six (6) monthly extensions, from December 9, 2024 to June 9, 2025 by depositing $60,000 into its trust account (the “ Trust Account ”) with Continental Stock Transfer and Trust Company (“ Continental ”). Globalink’s stockholders, at a special meeting of its stockholders held on December 3, 2024, approved an amendment to Globalink’s Amended and Restated Certificate of Incorporation, as amended (the “ Charter Amendment ”), and Globalink’s Investment Management Trust Agreement, as amended, originally entered into on December 6, 2021 with Continental (the “ Trust Agreement Amendment ”) to extend the deadline to complete Globalink’s initial business combination from December 9, 2024 to up to June 9, 2025 for up to six times of monthly extensions, by depositing into the Trust Account $60,000 prior to each one-month extension. The Charter Amendment triggered a right of Globalink’s public stockholders to demand the redemption of their public shares out of funds held in the Trust Account. Holders of 2,285,056 public shares properly requested redemption leaving 277,511 public shares outstanding. After payment of the redemption price to the redeeming public shareholders of approximately $11.77 per share for an aggregate of $26.89 million, Globalink will have approximately $3.27 million left in its Trust Account. As a consequence of the adoption of the Charter Amendment and the Trust Agreement Amendment and the redemptions, Globalink can now obtain up to six monthly extensions, or up until June 9, 2025, to complete its initial business combination at a cost of $60,000 per extension. About Globalink Investment Inc. Globalink is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although there is no restriction or limitation on what industry or geographic region, Globalink intends to pursue targets in North America, Europe, South East Asia, and Asia (excluding China, Hong Kong and Macau) in the technology industry, specifically within the medical technology and green energy sectors. Cautionary Statement Regarding Forward-Looking Statements Certain statements in this press release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “outlook,” “guidance” or the negative of those terms or other comparable terminology. These statements are based on the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause future events to differ materially from those in the forward-looking statements, many of which are outside of the Company’s control. These factors include, but are not limited to, a variety of risk factors affecting the Company’s business and prospects, see the section titled “Risk Factors” in the Company’s Prospectus filed with the SEC on December 6, 2021 and subsequent reports filed with the SEC, as amended from time to time. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Globalink Contact: Say Leong Lim Globalink Investment Inc. Telephone: +6012 405 0015 Email: sllim@globalinkinvestment.com
(The Center Square) – A political insider says the nature of Illinois politics has dramatically changed in the past two decades. Although Democrats won a majority of seats statewide, Republicans made some strides. President-elect Donald Trump won a larger percentage of the Illinois vote than he did four years ago. “The voters that were for Trump were concerned about inflation, the economy, immigration, and a judgment on the Biden Administration,” said Kent Redfield, professor of political science at the University of Illinois-Springfield during a University of Illinois-Extension webinar. “People were not pleased with the direction of the country.” During a recent news conference, Illinois House Republicans said they believe voters sent Democrats a message at the ballot box, and it’s time to change. “The residents of the state voted with their pocket books in mind. signaling a resounding call for better fiscal accountability and immediate relief,” said House Minority Leader Tony McCombie, R-Savanna. Redfield said Illinois Democrats have created a super majority simply by drawing legislative maps in their favor. “Democrats in drawing the maps have taken what is an advantage in terms of demographics and voting behaviors,” said Redfield. A report card from the Coalition Hub for Advancing Redistricting and Grassroots Engagement gave Illinois an “F” grade due to “egregious racial and partisan gerrymandering, or sorting voters based on race and partisanship.” Redfield said downstate Illinois continues to be mostly Republican, but the political scene is different now. “Dramatically within Illinois, we’ve gone from a party-centered kind of process to one that is much more candidate-centered,” said Redfield.Celebrations, Looting, And Statue Surfing: Scenes From Syria After Assad's Fall